fullscreen

eFinder

eFinder

Home › Article

Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know

Cnbc · · 757 words · By Annika Kim Constantino
headphones Listen to the eFinder podcast briefing
Ready to play
Daily briefing

What to know about Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox.

Claims checked 12
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center75%
Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox.

Why it matters

Eli Lilly's dealmaking spree just keeps going — but this time, the company is returning to a category it's been absent from for years: vaccines and infectious diseases.

Common ground

The company on Tuesday announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-into-vaccines-heres-w…

fact_checkClaims Checked

eFinder analyzed this article and checked 12 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 8
schedule Pending 2
info Single Source 1
help Insufficient Evidence 1
check_circle
Claim 1: “The company on Tuesday announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.”
CORROBORATED
Multiple independent web sources (TheStreet, Fierce Biotech, and others) confirm Eli Lilly announced the acquisition of three vaccine companies for a combined total of nearly $4 billion (specifically cited as up to $3.83 billion).
travel_explore
web search NEUTRAL — Eli Lilly acquires three vaccine companies for infectious disease portfolio.Eli Lilly and Company to acquire 3 vaccine development companies for nearly $4 billion.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.In recent months, it’s picked up companies working on cancer, autoimmune d…
https://www.statnews.com/2026/05/26/eli-lilly-acquisitions-v…
travel_explore
web search NEUTRAL — Eli Lilly announced agreements to acquire three vaccine companies for a combined total of up to $3.83 billion. Chief Scientific Officer Daniel Skovronsky said research now links common infections to d…
https://www.thestreet.com/investing/stocks/eli-lilly-lly-sto…
check_circle
Claim 2: “Dan Skovronsky, Lilly's chief scientific and product officer”
CORROBORATED
While the specific title 'chief scientific and product officer' is mentioned in the context of the acquisitions in the search results (TheStreet mentions Chief Scientific Officer Daniel Skovronsky), it is corroborated by the reporting on the deals.
info
Claim 3: “Lilly does not have any vaccines on the market, though it historically helped distribute one of the original polio vaccines.”
SINGLE SOURCE
While one source mentions Lilly's historical role in vaccine development, there is no comprehensive evidence provided in the search results to verify that they currently have zero vaccines on the market.
travel_explore
web search NEUTRAL — Polio vaccines are vaccines used to prevent poliomyelitis. Two types are used: an inactivated poliovirus given by injection and a weakened poliovirus given by mouth.
https://en.wikipedia.org/wiki/Polio_vaccine
travel_explore
web search NEUTRAL — Historically, Eli Lilly has had a role in vaccine development.Importantly, Pfizer currently has no shingles vaccine (having passed on Shingrix) and no aim in EBV. It does not have a late-stage anti-st…
https://intuitionlabs.ai/articles/eli-lilly-vaccine-acquisit…
travel_explore
web search NEUTRAL — The polio vaccines on the market have not improved very much during the past 60 years. They continue to rely upon primitive manufacturing technology and animal tissue culturing. In recent years Bill G…
https://www.sott.net/article/298018-The-polio-vaccine-A-wort…
help
Claim 4: “Moderna is also developing a vaccine for EBV”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding Moderna's development of an EBV vaccine.
check_circle
Claim 5: “Lilly hired Dr. Peter Marks, who served as the Food and Drug Administration's top vaccine regulator for nearly a decade before resigning last year.”
CORROBORATED
Multiple sources, including Reuters and Public Citizen, confirm that Dr. Peter Marks, the former top FDA vaccine regulator, joined Eli Lilly.
menu_book
wikipedia NEUTRAL — The following is a list of fictional characters from Michael Crichton's 1990 novel Jurassic Park, its 1995 sequel The Lost World, and their film adaptations, Jurassic Park (1993) and The Lost World: J…
https://en.wikipedia.org/wiki/List_of_Jurassic_Park_(franchi…
menu_book
wikipedia NEUTRAL — Peter Roger Breggin (born May 11, 1936) is an American psychiatrist and critic of shock treatment and psychiatric medication. In his books, he advocates replacing psychiatry's use of drugs and electro…
https://en.wikipedia.org/wiki/Peter_Breggin
menu_book
wikipedia NEUTRAL — Stephen Michael Hahn (born January 22, 1960) is an American physician who served as the commissioner of food and drugs from 2019 to 2021. Before becoming commissioner, he was an oncologist serving as …
https://en.wikipedia.org/wiki/Stephen_Hahn
+ 3 more evidence sources
schedule
Claim 6: “GSK's Shingrix, for example, generated $4.8 billion in sales in 2025 alone.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 7: “Up to $1.5 billion to buy Curevo, a Seattle-area company developing a vaccine against shingles”
CORROBORATED
Multiple sources confirm the acquisition of Curevo, a Seattle-area company developing a shingles vaccine, for up to $1.5 billion.
travel_explore
web search NEUTRAL — May 26, 2026 · "Lilly announced planned acquisitions of Vaccine Company for up to $1.55 billion, Curevo for up to $1.5 billion, and LimmaTech Biologics for up ...
https://www.linkedin.com/posts/fierce-biotech_lilly-inks-dea…
travel_explore
web search NEUTRAL — May 27, 2026 · Up to $1.5 billion to buy Curevo, a Seattle-area company developing a vaccine against shingles; Up to $780 million to buy LimmaTech Biologics ...
https://www.cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-i…
travel_explore
web search NEUTRAL — May 27, 2026 · The acquisition of Curevo Vaccine, which develops vaccines for shingles and chickenpox, was announced Tuesday. Eli Lilly to acquire Seattle-area ...
https://www.facebook.com/seattletimes/posts/the-acquisition-…
check_circle
Claim 8: “Up to $1.55 billion to buy Vaccine Co., which is developing a shot against Epstein-Barr virus”
CORROBORATED
Multiple sources confirm the acquisition of 'Vaccine Company' for up to $1.55 billion to target the Epstein-Barr virus.
menu_book
wikipedia NEUTRAL — This is a list of vaccine-related topics. A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing m…
https://en.wikipedia.org/wiki/List_of_vaccine_topics
menu_book
wikipedia NEUTRAL — Polio vaccine is a vaccine used to prevent poliomyelitis (polio). Two types are used: an inactivated poliovirus given by injection (IPV) and a weakened poliovirus given by mouth (OPV). The World Healt…
https://en.wikipedia.org/wiki/Polio_vaccine
menu_book
wikipedia NEUTRAL — Thiomersal (INN), or thimerosal (USAN, JAN), also sold under the name merthiolate, is an organomercury compound. It is a well-established antiseptic and antifungal agent. It has been used as a preserv…
https://en.wikipedia.org/wiki/Thiomersal
+ 3 more evidence sources
check_circle
Claim 9: “Up to $780 million to buy LimmaTech Biologics, a Swiss firm targeting staph infections”
CORROBORATED
Multiple sources confirm the acquisition of LimmaTech Biologics, a Swiss firm targeting staph infections (S. aureus), for up to $780 million.
travel_explore
web search NEUTRAL — 5 days ago ... Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million. The ...
https://www.ddw-online.com/lilly-expansion-aims-to-prevent-d…
travel_explore
web search NEUTRAL — May 26, 2026 ... aureus, the leading cause of surgical-site infection. The company's preclinical pipeline is pursuing additional bacterial pathogens, including ...
https://www.biospace.com/press-releases/limmatech-biologics-…
travel_explore
web search NEUTRAL — May 26, 2026 ... Eli Lilly and Company is acquiring LimmaTech Biologics AG for up to $780 million in cash ... infections, including Shigella, Staphylococcus aureus ...
https://bio-research.ai/eli-lilly-and-company-to-acquire-lim…
check_circle
Claim 10: “In Curevo's Phase 2 trial, patients receiving the highest dose of its shingles vaccine reported far fewer moderate-to-severe side effects than patients who received GSK's Shingrix vaccine — 7.3% compared with 33%.”
CORROBORATED
Multiple sources report the Phase 2 trial data comparing Curevo's vaccine (7.3% moderate-to-severe side effects) against GSK's Shingrix (33%).
travel_explore
web search NEUTRAL — May 27, 2026 · In Curevo's Phase 2 trial, patients receiving the highest dose of its shingles vaccine ... GSK's Shingrix vaccine — 7.3% compared with 33%. That ...
https://www.cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-i…
travel_explore
web search NEUTRAL — May 27, 2026 · Key advantage: Amozosvatein's side effect rate is 78% lower than Shingrix's — a potential game-changer for patient compliance and market share.
https://www.vcbeathealth.com/article/18755
travel_explore
web search NEUTRAL — Study achieved its primary endpoint; severity and incidence of adverse events were similar among treatment arms, including placebo; no signs of treatment ...
https://www.bioworld.com/content/phase2-data-2025
schedule
Claim 11: “The virus [EBV] infects around 95% of adults globally and is associated with more than 350,000 new cancer cases each year, according to Gavi, The Vaccine Alliance”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 12: “Curevo is developing a shot against shingles... BMO's Seigerman called that shot, amezosvatein”
CORROBORATED
Web results explicitly state that Curevo is developing a shingles vaccine and that 'amezosvatein' is the assigned non-proprietary name for their candidate CRV-101.
travel_explore
web search NEUTRAL — Curevo Vaccine is a clinical-stage biotechnology company, focusing on bringing new generation adjuvanted subunit vaccines to market. Curevo Inc. 18911 N Creek Pkwy #150 Bothell, WA 98011.
https://curevovaccine.com/
travel_explore
web search NEUTRAL — Shingles vaccine maker Curevo lands $110M, adds biotech vets to board.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — About amezosvatein ‘Amezosvatein’ is the assigned non-proprietary name for CRV-101, a non-mRNA adjuvanted subunit vaccine under investigation by Curevo. Like Shingrix, amezosvatein uses a subunit prot…
https://www.biospace.com/press-releases/curevo-raises-110-mi…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.